A Florida biopharmaceutical and diagnostics company is paying nearly $1.5 billion in stock for Elmwood Park-based diagnostics laboratory firm Bio-Reference Laboratories Inc.OPKO Health Inc. said ...
BioReference Laboratories Inc. in Elmwood Park acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche. The Harmony Prenatal Test, Ariosa’s non-invasive prenatal screening ...
BioReference Health, formerly known as BioReference Laboratories, and OPKO Health have agreed to pay $9.85 million to resolve alleged violations of the False Claims Act arising from BioReference’s ...
Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million ...
Elmwood Par, NJ, Aug. 01, 2019 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today that it has received a letter from Horizon Blue Cross Blue Shield of New Jersey (Horizon) ...
ELMWOOD PARK, N.J., May 13, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a strategic collaboration with the Westchester Medical Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback